Application
A. Western blot analysis on MCF7 cell lysate using anti-Phospho-ER alpha (S118) RabMAb (Cat. #AJ1268d); dilution 1:1,000. Cell lysates were (1) untreated, or (2) treated with b-Estradiol and EGF.Application
B. Immunohistochemical staining of untreated paraffin-embedded human breast adenocarcinoma using anti-Phospho-ER alpha (S118) RabMAb (Cat. #AJ1268d).Application
C. Immunohistochemical staining of Phosphatase-treated paraffin-embedded human breast adenocarcinoma using anti-Phospho-ER alpha (S118) RabMAb (Cat. #AJ1268d).Application
D. Immunofluorescent staining of untreated MCF-7 cells using anti-Phospho-ER alpha (S118) RabMAb (Cat. #AJ1268d).Application
E. Immunofluorescent staining of Phosphatase-treated MCF-7 cells using anti-Phospho-ER alpha (S118) RabMAb (Cat. #AJ1268d).| Product Name | ER alpha Antibody Phospho (pS118) |
|---|---|
| Antibody Type | Primary Antibodies |
| Modification | p-S118 |
| Clonality | Monoclonal |
|---|---|
| Clone Number | E91 |
| Host Species | Rabbit |
| Tested Applications | WBIHCIF |
| WB:1:500 IHC |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Gene Synonyms | ESR, NR3A1 |
|---|---|
| Alternative Names | ESR1 ESR NR3A1 Estrogen receptor Estradiol receptor ER-alpha Nuclear receptor subfamily 3 group A member 1 |
| Molecular Weight(MW) | 66216 Da |
| Function | Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA- binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF- kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA- binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full length receptor. Isoform 3 can bind to ERE and inhibit isoform 1 |
| Tissue Specificity | Widely expressed. Isoform 3 is not expressed in the pituitary gland |
| Cellular Localization | Isoform 1: Nucleus. Cytoplasm. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Note=A minor fraction is associated with the inner membrane Nucleus. Golgi apparatus. Cell membrane. Note=Colocalizes with ZDHHC7 and ZDHHC21 in the Golgi apparatus where most probably palmitoylation occurs. Associated with the plasma membrane when palmitoylated |
| Entrez Gene | 2099 |
|---|
Application
A. Western blot analysis on MCF7 cell lysate using anti-Phospho-ER alpha (S118) RabMAb (Cat. #AJ1268d); dilution 1:1,000. Cell lysates were (1) untreated, or (2) treated with b-Estradiol and EGF.
Application
B. Immunohistochemical staining of untreated paraffin-embedded human breast adenocarcinoma using anti-Phospho-ER alpha (S118) RabMAb (Cat. #AJ1268d).
Application
C. Immunohistochemical staining of Phosphatase-treated paraffin-embedded human breast adenocarcinoma using anti-Phospho-ER alpha (S118) RabMAb (Cat. #AJ1268d).
Application
D. Immunofluorescent staining of untreated MCF-7 cells using anti-Phospho-ER alpha (S118) RabMAb (Cat. #AJ1268d).
Application
E. Immunofluorescent staining of Phosphatase-treated MCF-7 cells using anti-Phospho-ER alpha (S118) RabMAb (Cat. #AJ1268d).| Application Notes | WB:1:500 IHC |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA. |
